US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skycorp Solar Group Limited

2.44

+0.07002.95%

Post-market: 2.500.0600+2.46%19:52 EDT

Volume:211.76K

Turnover:521.05K

Market Cap:65.88M

PE:129.52

High:2.57

Open:2.41

Low:2.41

Close:2.37

Loading ...

Overview Company News Filings

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Skycorp Solar Group Ltd. Announces Resignation of COO Gaokui Zhang Due to Health Reasons

BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And Development

Skycorp Solar Group Ltd - to Allocate Funds Cautiously for Pv Plant Projects

THOMSON REUTERS

Skycorp Solar Group Announces Board Authorization for Solar Photovoltaic Power Plant Acquisitions and Development

THOMSON REUTERS

Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

Skycorp Solar showcases PV cable, connection solutions at SNEC 2025

Commentary: Next challenge for PM Anwar’s PKR - keeping its anchor role in government

1 minister’s defection, 2 unhappy political parties: Trouble brewing in Malaysia’s ruling coalition?

Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well

MT Newswires Live

Powell Max Limited Terminates Key Agreements with YA II PN Ltd.

Outcome in race for No 2 in Anwar’s party could pose political headache for him

Celularity Extends Note Maturity with YA II PN

Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

Skycorp Solar Group Ltd - to Localize Operations in the United States

THOMSON REUTERS

Skycorp Solar Group Limited Rings Nasdaq Opening Bell, Unveils Strategic Expansion Into U.S. Solar Market

THOMSON REUTERS

Malaysian footballer acid attack: ‘No further action’ from public prosecutor but police will continue probe

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","market":"US","secType":"STK","nameCN":"Skycorp Solar Group Limited","latestPrice":2.44,"timestamp":1752868800000,"preClose":2.37,"halted":0,"volume":211761,"hourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.44,"latestTime":"19:52 EDT","volume":430,"amount":1072.39,"timestamp":1752882739875},"delay":0,"floatShares":10349999,"shares":27000000,"eps":0.018839,"marketStatus":"Market Closed","change":0.07,"latestTime":"07-18 16:00:00 EDT","open":2.41,"high":2.57,"low":2.41,"amount":521046.5701,"amplitude":0.067511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.018839,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1741064400000,"exchange":"NASDAQ","adjPreClose":2.37,"postHourTrading":{"tag":"盘后","latestPrice":2.5,"preClose":2.44,"latestTime":"19:52 EDT","volume":430,"amount":1072.39,"timestamp":1752882739875},"volumeRatio":1.0390123905111723},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PN\",,,,,undefined,":{"symbol":"PN","floatShares":10349999,"roa":"2.28%","roe":"6.51%","lyrEps":0.018839,"volumeRatio":1.0390123905111723,"shares":27000000,"dividePrice":0,"high":2.57,"amplitude":0.067511,"preClose":2.37,"low":2.41,"week52Low":2.11,"pbRate":"4.01","psRate":"1.32","week52High":4.45,"institutionHeld":0,"latestPrice":2.44,"eps":0.018839,"divideRate":0,"volume":211761,"delay":0,"ttmEps":0.018839,"open":2.41,"prevYearClose":4,"prevWeekClose":2.41,"prevMonthClose":2.767,"prevQuarterClose":2.767,"fiveDayClose":2.41,"twentyDayClose":2.77,"sixtyDayClose":2.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552995694","title":"European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2552995694","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552995694?lang=en_us&edition=fundamental","pubTime":"2025-07-18 23:30","pubTimestamp":1752852600,"startTime":"0","endTime":"0","summary":"– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/18/3118039/0/en/European-Commission-Grants-Conditional-Approval-of-EZMEKLY-mirdametinib-for-the-Treatment-of-Adult-and-Pediatric-Patients-with-NF1-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","PN","BK4156","EC","BK4201","ORR"],"gpt_icon":0},{"id":"2552431392","title":"Skycorp Solar Group Ltd. Announces Resignation of COO Gaokui Zhang Due to Health Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2552431392","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552431392?lang=en_us&edition=fundamental","pubTime":"2025-07-18 04:00","pubTimestamp":1752782456,"startTime":"0","endTime":"0","summary":"Skycorp Solar Group Ltd. has announced the resignation of its Chief Operating Officer, Gaokui Zhang, due to health reasons. His resignation will be effective on July 17, 2025. The company clarified that his departure is not related to any disagreements or issues concerning business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skycorp Solar Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL4RFqLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PN","BK4096"],"gpt_icon":0},{"id":"2548942801","title":"BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2548942801","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548942801?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:00","pubTimestamp":1751544051,"startTime":"0","endTime":"0","summary":"BRIEF-Skycorp Solar Group Announces Board Authorization For Solar Photovoltaic Power Plant Acquisitions And DevelopmentJuly 3 (Reuters) - Skycorp Solar Group Ltd PN.O:SKYCORP SOLAR GROUP ANNOUNCES BOA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nTUA4ZYZTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2548801913","title":"Skycorp Solar Group Ltd - to Allocate Funds Cautiously for Pv Plant Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2548801913","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548801913?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:00","pubTimestamp":1751544000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nTUA4ZYZTP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2548280156","title":"Skycorp Solar Group Announces Board Authorization for Solar Photovoltaic Power Plant Acquisitions and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2548280156","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548280156?lang=en_us&edition=fundamental","pubTime":"2025-07-03 20:00","pubTimestamp":1751544000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nTUA4ZYZTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2548877230","title":"Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2548877230","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548877230?lang=en_us&edition=fundamental","pubTime":"2025-07-01 20:30","pubTimestamp":1751373000,"startTime":"0","endTime":"0","summary":"SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks portfolio and pimicotinib. DARMSTADT, Germany, July 01, 2025----Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion *, following regulatory clearances and the fulfillment of other customary closing conditions.The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck KGaA, Darmstadt, Germany’s revenues and is expected to be accretive to the company’s ear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-completes-123000978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4096","PN","BK4137","BK4539","LENZ","AAQC","CHMP","BK4081","BK4139","MKGAF","BK4087","HCSG","EMA"],"gpt_icon":0},{"id":"2543867274","title":"Skycorp Solar showcases PV cable, connection solutions at SNEC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2543867274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543867274?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:15","pubTimestamp":1750076149,"startTime":"0","endTime":"0","summary":"Skycorp Solar (PN) Group highlighted its latest innovations at the 18th SNEC International Photovoltaic Power Generation and Smart Energy Conferenc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skycorp-solar-showcases-pv-cable-connection-solutions-at-snec-2025-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skycorp-solar-showcases-pv-cable-connection-solutions-at-snec-2025-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2542035656","title":"Commentary: Next challenge for PM Anwar’s PKR - keeping its anchor role in government","url":"https://stock-news.laohu8.com/highlight/detail?id=2542035656","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542035656?lang=en_us&edition=fundamental","pubTime":"2025-06-10 06:00","pubTimestamp":1749506400,"startTime":"0","endTime":"0","summary":"The Parti Keadilan Rakyat leadership elections turned out to be intense and not without controversy. But Prime Minister Anwar Ibrahim’s party has a far bigger challenge ahead, says this public policy consultant.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--4UXq6QyY--/c_crop,h_700,w_1245,x_173,y_35/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2023/07/12/anwar%20ibrahim%20ahmad%20zahid%20seat%20distribution.jpg?itok=t7N44mId","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--4UXq6QyY--/c_crop,h_700,w_1245,x_173,y_35/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2023/07/12/anwar%20ibrahim%20ahmad%20zahid%20seat%20distribution.jpg?itok=t7N44mId"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/commentary/malaysia-pm-anwar-pkr-unity-government-challenge-5171156","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU0256863811.USD","LU1988902786.USD","LU1989772840.SGD","PN","LU0256863902.USD","IE00B3S45H60.SGD","IE00B775SV38.USD","LU2264538146.SGD","BN","BK4588","LU0320765489.SGD","BK4096","LU1064131342.USD","PH","LU1989772923.USD","LU0417517546.SGD","LU0070302665.USD","LU0211331839.USD","BK4161","BK4580","BK4135","LU0208291251.USD","BK4585"],"gpt_icon":0},{"id":"2541761020","title":"1 minister’s defection, 2 unhappy political parties: Trouble brewing in Malaysia’s ruling coalition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541761020","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541761020?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:05","pubTimestamp":1749125100,"startTime":"0","endTime":"0","summary":"The resignation of Investment, Trade and Industry Minister Tengku Zafrul Abdul Aziz from UMNO to ally PKR has posed questions on the ruling coalition’s future and also whether he’s a dark horse in succeeding PM Anwar Ibrahim.","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s---xnD2lE8--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/05/img_5944.jpg?itok=0IA4febj","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s---xnD2lE8--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/05/img_5944.jpg?itok=0IA4febj"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-tengku-zafrul-pkr-umno-anwar-ibrahim-5167361","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU0256863902.USD","LU0417517546.SGD","5GC.SI","BK4585","LU1064131342.USD","BK4132","LU1988902786.USD","PH","LU1989772840.SGD","LU1989772923.USD","USM","LU2264538146.SGD","LU0256863811.USD","LU0320765489.SGD","BK4168","PN","BK4161","LU0070302665.USD","LU0211331839.USD","LU0208291251.USD","BK4096","IE00BD6J9T35.USD","BK4588","BK4580"],"gpt_icon":1},{"id":"2539250287","title":"Intellia Says Enrollment in Late-Stage Study of NTLA-2002 on Track, of Nex-Z for ATTRv-PN Progressing Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2539250287","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539250287?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:26","pubTimestamp":1748521617,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.Shares of the company were down by more than 20% in recent Thursday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","SSI","BK4535","LU1861559042.SGD","BK4556","NTLA","BK4588","BK4096","PN","LU1861558580.USD","BK4139"],"gpt_icon":0},{"id":"2537137351","title":"Powell Max Limited Terminates Key Agreements with YA II PN Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2537137351","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537137351?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:50","pubTimestamp":1748008213,"startTime":"0","endTime":"0","summary":"Powell Max Limited Class A ( ($PMAX) ) just unveiled an update. On May 23, 2025, Powell Max Limited, a company incorporated in the British Virgin I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/powell-max-limited-terminates-key-agreements-with-ya-ii-pn-ltd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/powell-max-limited-terminates-key-agreements-with-ya-ii-pn-ltd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","PMAX","US12M.BOND","US10Y.BOND","US2Y.BOND","US3Y.BOND","US6M.BOND","BK4112","US7Y.BOND","US30Y.BOND","PN","GPRO","US5Y.BOND","BK4078"],"gpt_icon":0},{"id":"2537763972","title":"Outcome in race for No 2 in Anwar’s party could pose political headache for him","url":"https://stock-news.laohu8.com/highlight/detail?id=2537763972","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537763972?lang=en_us&edition=fundamental","pubTime":"2025-05-23 06:00","pubTimestamp":1747951200,"startTime":"0","endTime":"0","summary":"Anwar’s daughter, Nurul Izzah, is touted as a favourite to beat incumbent Rafizi Ramli, who has said he would resign as Economy Minister if he loses.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--NTa5mR_q--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/22/composite_1.jpg?itok=MwkQEPxP","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--NTa5mR_q--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/05/22/composite_1.jpg?itok=MwkQEPxP"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-pkr-number-two-race-nurul-izzah-rafizi-ramli-anwar-5144421","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU0256863811.USD","LU1988902786.USD","LU1989772923.USD","LU0211331839.USD","LU1064131342.USD","LU0208291251.USD","PN","LU1989772840.SGD","5GC.SI","LU0070302665.USD","BK4161","BK4096","LU0256863902.USD","LU0320765489.SGD","BK4585","PH","BK4580","LU0417517546.SGD","LU2264538146.SGD","BK4588"],"gpt_icon":0},{"id":"2537370626","title":"Celularity Extends Note Maturity with YA II PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2537370626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537370626?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:20","pubTimestamp":1747776024,"startTime":"0","endTime":"0","summary":"Celularity ( ($CELU) ) has issued an update. On May 20, 2025, Celularity Inc. entered into a letter agreement with YA II PN, Ltd. to extend the mat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/celularity-extends-note-maturity-with-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/celularity-extends-note-maturity-with-ya-ii-pn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2537647397","title":"Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2537647397","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537647397?lang=en_us&edition=fundamental","pubTime":"2025-05-21 01:25","pubTimestamp":1747761913,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-attr-pn-trial-shows-promising-long-term-efficacy-justifying-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/intellia-therapeutics-attr-pn-trial-shows-promising-long-term-efficacy-justifying-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTLA","PN"],"gpt_icon":0},{"id":"2534969485","title":"Skycorp Solar Group Ltd - to Localize Operations in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2534969485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534969485?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:00","pubTimestamp":1746792000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA5SJKZ9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4096","PN"],"gpt_icon":0},{"id":"2534485556","title":"Skycorp Solar Group Limited Rings Nasdaq Opening Bell, Unveils Strategic Expansion Into U.S. Solar Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2534485556","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534485556?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:00","pubTimestamp":1746792000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA5SJKZ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PN","BK4096"],"gpt_icon":0},{"id":"2534177157","title":"Malaysian footballer acid attack: ‘No further action’ from public prosecutor but police will continue probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177157","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177157?lang=en_us&edition=fundamental","pubTime":"2025-05-09 14:49","pubTimestamp":1746773340,"startTime":"0","endTime":"0","summary":"National footballer and winger for Selangor FC Faisal Halim suffered fourth-degree burns from an acid attack on May 5 last year and had to undergo four surgeries.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--Li5IBXWT--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/one-cms/core/a44c088c7a337328bd491262c4ea1b345762ec94.jpg?itok=Te80N0rz","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--Li5IBXWT--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2023-11:afp_watermark_14112023,w_0.1/f_auto,q_auto/v1/one-cms/core/a44c088c7a337328bd491262c4ea1b345762ec94.jpg?itok=Te80N0rz"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/malaysia-faisal-halim-acid-footballer-attack-selangor-fc-no-further-action-5119301","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["ICU","BK4096","BK4082","PN"],"gpt_icon":0},{"id":"2533632035","title":"Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2533632035","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533632035?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:01","pubTimestamp":1746475260,"startTime":"0","endTime":"0","summary":"Phase 2 study fully enrolled; data expected in 2H 2025. HAMPTON, N.J., May 05, 2025  -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis . Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week  2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 study is complete and that clinical results are expected in the second half of 2025.Phase 2 EvolvE presentation details: “Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-presents-histology-data-phase-200100954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLDX","PN","BK4096","PMC"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4205","LU2242646821.SGD","TCS","BK4585","BK4233","LU0868494617.USD","SLE","IE0002141913.USD","LU1057294990.SGD","BK4096","BK4599","LU2112291526.USD","TCI","BK4211","LU0289739699.SGD","LU0058720904.USD","BK4581","FCF","LU0122379950.USD","BK4188","IE0009355771.USD","BK4566","BK4533","IE00BFTCPJ56.SGD","LU2242652126.USD","PN","AMGN","MPA","TSLP","LU2089984988.USD","MTA","BK4077","LU1983299246.USD","BK4200","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IE00B2B36J28.USD","LU0889565916.HKD","BK4160","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4139","LU0109394709.USD","SG9999001440.SGD","LU1061106388.HKD","GIPR","LU0320765992.SGD","BK4534"],"gpt_icon":0},{"id":"2532070899","title":"Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070899","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070899?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease  and asthma. COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation. Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase 2 trial designed to study Dupixent in allergic bronchopulmonary aspergillosis  in patients with asthma. COPD data assess Dupixent impact on lung function and exacerbations in COPD, including patients with or without emphysema Notable abstracts in COPD will highlight new results from the pivotal landmark Phase 3 BOREAS and NOTUS trials, including analyses demonstrating Dupixent reduced exacerbations and improved lung function regardless of whether patients had emphysema. In the pivotal COPD trials, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupixent-dupilumab-data-presented-ats-130000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","LU2237438978.USD","LU0109394709.USD","LU0289739699.SGD","PT","ATS","LU2362540622.SGD","LU2023250504.SGD","LU2468319806.SGD","LU1917777945.USD","LU0053666078.USD","BK4166","LU0889565916.HKD","BK4161","LU2362541513.USD","LU0114720955.EUR","LU0058720904.USD","BK4588","LU0882574055.USD","LU2362541273.HKD","REGN","LU1974910355.USD","BK4096","BK4139","LU2089984988.USD","LU2106854487.HKD","BK4585","LU0823416689.USD","PN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PN","date":"2025-07-18","current":135.863623,"percent":0.042553,"low":126.634068,"twenty":143.316058,"median":158.220928,"eighty":203.859639,"high":257.968904,"avg":167.935825,"sd":30.506751,"marketCap":63990000},"quantilePoints":[{"date":"2025-03-07","current":218.413672,"twenty":221.509299,"median":227.299267,"eighty":241.802853,"marketCap":102870000},{"date":"2025-03-14","current":216.120615,"twenty":215.432698,"median":218.413672,"eighty":226.554024,"marketCap":101790000},{"date":"2025-03-21","current":214.974086,"twenty":214.74478,"median":217.840407,"eighty":223.401071,"marketCap":101250000},{"date":"2025-03-28","current":174.84559,"twenty":214.171516,"median":218.413672,"eighty":223.802356,"marketCap":82350000},{"date":"2025-04-04","current":196.629631,"twenty":205.707843,"median":216.693879,"eighty":223.802356,"marketCap":92610000},{"date":"2025-04-11","current":174.84559,"twenty":185.164346,"median":214.974086,"eighty":223.401071,"marketCap":82350000},{"date":"2025-04-17","current":144.462586,"twenty":175.992118,"median":213.827558,"eighty":222.942459,"marketCap":68040000},{"date":"2025-04-25","current":146.182379,"twenty":169.571559,"median":205.245792,"eighty":221.738604,"marketCap":68850000},{"date":"2025-05-02","current":139.876472,"twenty":146.182379,"median":196.629631,"eighty":219.789506,"marketCap":65880000},{"date":"2025-05-09","current":142.169529,"twenty":144.462586,"median":179.718336,"eighty":218.413672,"marketCap":66960000},{"date":"2025-05-16","current":143.241533,"twenty":143.318351,"median":174.84559,"eighty":217.95506,"marketCap":67464900},{"date":"2025-05-23","current":161.087249,"twenty":143.318351,"median":174.05162,"eighty":216.808532,"marketCap":75870000},{"date":"2025-05-30","current":166.246627,"twenty":143.435296,"median":166.533259,"eighty":216.020867,"marketCap":78300000},{"date":"2025-06-06","current":170.832741,"twenty":144.003975,"median":164.526834,"eighty":215.492317,"marketCap":80460000},{"date":"2025-06-13","current":161.087249,"twenty":144.462586,"median":163.380306,"eighty":214.859433,"marketCap":75870000},{"date":"2025-06-20","current":158.794192,"twenty":144.462586,"median":162.520409,"eighty":214.400822,"marketCap":74790000},{"date":"2025-06-27","current":148.475436,"twenty":144.462586,"median":162.233777,"eighty":213.827558,"marketCap":69930000},{"date":"2025-07-03","current":134.717094,"twenty":144.462586,"median":161.087249,"eighty":212.451724,"marketCap":63450000},{"date":"2025-07-11","current":144.462586,"twenty":143.775816,"median":159.914923,"eighty":208.466391,"marketCap":68040000},{"date":"2025-07-18","current":135.863623,"twenty":143.316058,"median":158.220928,"eighty":203.859639,"marketCap":63990000}],"updateTime":1752923473825}}}